Product Overview
QUADRAMET® (SAMARIUM SM 153 LEXIDRONAM INJECTION) — A THIRD-GENERATION RADIOPHARMACEUTICAL
PHOSPHONATE TARGETING + BENEFITS OF RADIOTHERAPY
- More QUADRAMET accumulates in osteoblastic lesions with a lesion-to-normal bone ratio of approximately 51
- Indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan
QUADRAMET is a therapeutic agent consisting of radioactive samarium and a tetraphosphonate chelator, ethylenediaminetetramethylenephosphonic acid (EDTMP).
QUADRAMET IS A UNIQUE RADIOPHARMACEUTICAL
- Short half-life radionuclide—1.93 days1 Both beta- and gamma-emitting
- Radiation deposited primarily in bone, with limited penetration of the marrow space2
| Radionuclide | Half-life | β emission | γ emission | Penetration |
|---|---|---|---|---|
| Samarium-153 | 1.93 days | 0.22 MeV | 103 keV | 0.55 mm |
| Strontium-89 | 50.5 days | 0.58 MeV | none | 2.4 mm |
Data from reference 2.
PHARMACOLOGY
- Bisphosphonates do not interfere with the skeletal uptake of QUADRAMET3, 4
- Uptake: the greater the number of metastatic lesions, the more skeletal uptake of Sm-153 radioactivity1
- Clearance <1% of the dose injected remains in the blood 5 hours after injection 1
- Pharmacodynamics: the beta particle of 153Sm-EDTMP travels an average of 3.1 mm in soft tissue and 1.7 mm in bone1
REFERENCES:
- Quadramet (samarium Sm-153 lexidronam injection) prescribing information. September 2003.
- Sartor O. Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol. 2004;6(suppl 10):S3-S12.
- Marcus CS, Saeed S, Mlikotic A, et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin Nuc Med. 2002;27:427-430.
- Data on file, EUSA Pharma.
